Skip to main content

Table 2 Univariable Cox regression analysis of factors affecting survival at 18 months in the whole group of patients

From: The effect of primary tumor radiotherapy in patients with Unresectable stage IV Rectal or Rectosigmoid Cancer: a propensity score matching analysis for survival

Factors

Number (%)

HR (95% CI)

P value

Age

  < 60 years

162 (46.29)

Reference

 

  ≥ 60 years

188 (53.71)

0.98 (0.97, 1.00)

0.0297

Sex

 Male

254 (72.57)

Reference

 

 Female

96 (27.43)

0.88 (0.62, 1.26)

0.4927

KPS

 70–80

242 (69.14)

Reference

 

 90–100

108 (30.86)

1.00 (0.98, 1.03)

0.7220

Primary Site

 Rectum

266 (76.00)

Reference

 

 Rectosigmoid

84 (24.00)

1.12(0.53,1.18)

0.6210

T Stage

 T2

24 (6.86)

Reference

 

 T3

176 (50.29)

2.86 (1.05, 7.83)

0.0406

 T4

150 (42.86)

3.16 (1.15, 8.64)

0.0253

N Stage

 N0

50 (14.29)

Reference

 

 N1

114 (32.57)

0.88 (0.44, 1.75)

0.7192

 N2

86 (24.57)

2.03 (1.05, 3.93)

0.0350

 N+

86 (24.57)

4.09 (2.21, 7.59)

< 0.0001

 Nx

14 (4.00)

7.01 (3.14, 15.66)

< 0.0001

M Stage

 M1a

180 (51.43)

Reference

 

 M1b

146 (41.71)

1.09 (0.77, 1.54)

0.6163

 M1c

24 (6.86)

2.39 (1.46, 3.91)

0.0006

Differentiation

 Well

28 (8.00)

Reference

 

 Moderate

198 (56.57)

0.28 (0.17, 0.47)

< 0.0001

 Poor

110 (31.43)

1.00 (0.61, 1.65)

0.9877

 Unknown

14 (4.00)

0.95 (0.22, 4.07)

0.9444

Chemotherapy Cycles

 4–8

247(70.57)

Reference

 

 9–12

103(29.43)

0.79 (0.69, 0.90)

0.0002

Second-line Chemotherapy

 No

276 (78.86)

Reference

 

 Yes

74 (21.14)

0.37 (0.22, 0.63)

0.0002

Chemotherapy Response

 Poor

146 (41.71)

Reference

 

 Good

204 (58.29)

0.82 (0.59, 1.13)

0.0217

Metastatic Tumor radiotherapy

 Yes

180 (51.43)

Reference

 

 No

170 (48.57)

1.53 (1.11, 2.11)

0.0102

Primary Tumor Radiotherapy

 No

187 (53.43)

Reference

 

 Yes

163 (46.57)

0.39 (0.28, 0.56)

< 0.0001